Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancerYingjie Lu, Zhenghong Zhu|Molecular Medicine Reports|2020Cited by 29